BMP 7 Human

Bone Morphogenetic Protein-7 Human Recombinant
Shipped with Ice Packs
In Stock

Description

BMP-7 regulates diverse processes through Smad-dependent and Smad-independent pathways:

Key Roles

  • Osteogenesis: Induces mesenchymal stem cell differentiation into osteoblasts via Smad1/5/8 phosphorylation and Runx2 activation .

  • Organ Development: Critical for kidney morphogenesis, eye formation, and neural tube patterning .

  • Anti-Fibrotic Activity: Reverses epithelial-to-mesenchymal transition (EMT) in renal and cardiac tissues .

  • Immunomodulation: Modulates Langerhans cell differentiation and T-cell polarization .

Signaling Pathways

PathwayMechanismOutcome
Canonical (Smad)BMP-7 → BMPR-II → Smad1/5/8 → Nuclear translocation → Osteogenic gene expression Bone formation, anti-apoptotic effects
Non-CanonicalActivates MAPK (p38, JNK) and PI3K/Akt pathways Cell proliferation, fibrosis inhibition

Approved Uses

  • Orthopedics: rhBMP-7 (OP-1) is FDA-approved for long bone non-unions and spinal fusion .

  • Renal Disease: Reduces fibrosis in chronic kidney injury models .

Emerging Applications

ConditionEffectStudy Outcome
Gastric CancerHigh BMP-7 expression correlates with advanced stage and poor prognosis 5-year survival: 45% (BMP-7+) vs. 75% (BMP-7–)
NeuroregenerationPromotes recovery in ischemic brain injury models Enhanced neuronal outgrowth and differentiation
AdipogenesisInduces brown adipocyte differentiation, enhancing thermogenesis Potential anti-obesity therapy target

Recent Advances

  • Fibrosis Reversal: BMP-7 suppresses TGF-β1-driven fibrosis in lung, liver, and peritoneal tissues .

  • Cancer Biology: Dual role observed: inhibits metastasis in prostate cancer but promotes aggressiveness in gastric malignancies .

  • Immunotherapy: BMP-7-generated Langerhans cells exhibit superior T-cell stimulatory capacity compared to TGF-β1-induced cells .

Comparative Efficacy

Therapeutic AgentAdvantageLimitation
rhBMP-7Low immunogenicity; broad anti-fibrotic effectsLess potent osteoinduction vs. rhBMP-2
rhBMP-2Faster bone regenerationHigher risk of heterotopic ossification

Detection and Quantification

The Quantikine™ ELISA kit detects BMP-7 in serum, plasma, and urine with a sensitivity of 2.44 pg/mL . Recovery rates exceed 90% across matrices, enabling reliable clinical monitoring .

Challenges and Future Directions

While BMP-7’s pleiotropic effects offer therapeutic promise, challenges include:

  • Dose-Dependent Effects: Low doses promote proliferation (via MAPK), while high doses inhibit it (via Smad) .

  • Contextual Signaling: Opposite roles in cancer (pro-tumorigenic vs. anti-metastatic) necessitate tissue-specific targeting .

Product Specs

Introduction
Bone morphogenetic proteins (BMPs) belong to the transforming growth factor-beta (TGFB) superfamily and are known for their ability to induce bone growth. Initially discovered for their capacity to stimulate endochondral osteogenesis at extraskeletal sites, BMPs play a crucial role in early embryonic development. The BMP described here is closely related to BMP5 and BMP7, suggesting potential bone-inductive properties.
Description
Recombinant Human Bone Morphogenetic Protein-7, produced in E. coli, is a monomeric, non-glycosylated polypeptide chain with a molecular weight of 15679.97 Daltons, comprising 139 amino acids. This protein is purified using proprietary chromatographic techniques.
Physical Appearance
White, sterile, lyophilized powder.
Formulation
BMP-7 is lyophilized from a sterile solution at a concentration of 1 mg/ml in 10 mM sodium citrate buffer with a pH of 3.5.
Solubility
Before opening the vial, it is recommended to briefly centrifuge it to ensure the contents are at the bottom. Reconstitute the lyophilized powder in 20-100 mM acetic acid to achieve a concentration of 0.1-0.5 mg/ml. Divide the reconstituted solution into working aliquots and store them at temperatures below -20°C. Further dilutions should be made using suitable buffered solutions.
Stability
Lyophilized BMP-7 remains stable at room temperature for up to 3 weeks. However, it is recommended to store the lyophilized product desiccated at temperatures below -18°C. Once reconstituted, BMP-7 should be stored at 4°C for 2-7 days. For long-term storage, freeze at temperatures below -18°C. Adding a carrier protein (0.1% HSA or BSA) is recommended for long-term storage. Avoid repeated freeze-thaw cycles.
Purity
The purity is determined to be greater than 95% using the following methods: (a) Reverse-phase high-performance liquid chromatography (RP-HPLC) (b) Sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
Synonyms
Osteogenic Protein 1, BMP-7.
Source
Escherichia Coli.
Amino Acid Sequence
The sequence of the first five N-terminal amino acids was determined and was found to be Ser-Thr-Gly-Ser-Lys.

Product Science Overview

Introduction

Bone Morphogenetic Protein-7 (BMP-7), also known as Osteogenic Protein-1 (OP-1), is a member of the Transforming Growth Factor-beta (TGF-β) superfamily. This group of proteins is known for their role in regulating cell growth, differentiation, and apoptosis. BMP-7 is particularly notable for its osteoinductive properties, meaning it can induce the formation of bone and cartilage. It plays a crucial role in the development of the kidney, eye, and limb, as well as in the repair of bone fractures .

Discovery and Function

BMP-7 was first identified by its ability to induce endochondral osteogenesis in vivo at extraskeletal sites. This discovery was made by Professor Marshall Urist and Professor Hari Reddi, who demonstrated that demineralized bone extract could induce ectopic bone formation in rats . BMP-7 functions by promoting the differentiation of mesenchymal cells into bone and cartilage cells. It is a secreted multifunctional growth factor that forms a disulfide-linked homodimer, which is essential for its biological activity .

Recombinant BMP-7

Recombinant human BMP-7 (rhBMP-7) is produced using recombinant DNA technology. This involves cloning the BMP-7 gene into a suitable expression system, such as mammalian cells, to produce the protein in large quantities. The recombinant protein is then purified and used for various medical applications. rhBMP-7 has been approved by the Food and Drug Administration (FDA) for specific uses, including spinal fusions and the treatment of nonunion fractures .

Medical Applications

rhBMP-7 is used in orthopedic applications such as spinal fusions, nonunions, and oral surgery. It has also shown potential in the treatment of chronic kidney disease (CKD). Studies have demonstrated that BMP-7 can reverse the loss of glomeruli due to sclerosis in murine models . Additionally, BMP-7 has been used in clinical trials for bone repair and has shown promising results in promoting bone formation and healing .

Production and Purification

The production of rhBMP-7 involves several steps:

  1. Gene Cloning: The full-length sequence of BMP-7 is amplified and cloned into a suitable vector.
  2. Expression: The vector is introduced into mammalian cells, such as CHO or 293T cells, which then produce the BMP-7 protein.
  3. Purification: The protein is purified from the conditioned medium of the cells. This often involves multiple chromatography steps to ensure high purity.
  4. Characterization: The purified protein is characterized to confirm its identity, purity, and biological activity. This includes tests such as western blotting, glycosylation analysis, and bioactivity assays .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2024 Thebiotek. All Rights Reserved.